Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Sanara MedTech (SMTI) Operating Expenses (2016 - 2025)

Historic Operating Expenses for Sanara MedTech (SMTI) over the last 15 years, with Q3 2025 value amounting to $21.5 million.

  • Sanara MedTech's Operating Expenses rose 1384.73% to $21.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $98.9 million, marking a year-over-year increase of 3320.29%. This contributed to the annual value of $85.2 million for FY2024, which is 3894.83% up from last year.
  • As of Q3 2025, Sanara MedTech's Operating Expenses stood at $21.5 million, which was up 1384.73% from $23.9 million recorded in Q2 2025.
  • Sanara MedTech's 5-year Operating Expenses high stood at $29.8 million for Q4 2024, and its period low was $5.6 million during Q1 2021.
  • For the 5-year period, Sanara MedTech's Operating Expenses averaged around $15.8 million, with its median value being $15.4 million (2023).
  • Its Operating Expenses has fluctuated over the past 5 years, first soared by 9619.37% in 2022, then skyrocketed by 35.67% in 2023.
  • Sanara MedTech's Operating Expenses (Quarter) stood at $9.7 million in 2021, then surged by 66.31% to $16.1 million in 2022, then increased by 0.36% to $16.1 million in 2023, then surged by 84.59% to $29.8 million in 2024, then fell by 27.72% to $21.5 million in 2025.
  • Its last three reported values are $21.5 million in Q3 2025, $23.9 million for Q2 2025, and $23.7 million during Q1 2025.